Skip to main content
main-content
Top

04-05-2022 | COVID-19 | News

News in brief

Colchicine prophylaxis associated with ‘markedly reduced’ gout flare risk after COVID-19 vaccination

Author: Claire Barnard

share
SHARE
print
PRINT
insite
SEARCH

medwireNews: COVID-19 vaccination with inactivated virus vaccines is associated with an increased risk for flares among men with gout, and colchicine prophylaxis may help reduce this risk, researchers report.

Changgui Li (The Affiliated Hospital of Qingdao University, China) and colleagues’ study included 549 people with gout (96.7% men, median age 39 years), 462 of whom received an inactivated virus COVID-19 vaccine. In all, 43.9% of vaccinated individuals experienced gout flares in the 3 months following vaccination, most commonly in the first month after receipt of their first or second dose.

Multivariate analysis demonstrated that vaccination was associated with a significantly increased risk for gout flare, with an odds ratio (OR) of 6.02 after adjustment for factors including age, BMI, and prevaccination serum urate levels.

Nevertheless, the 114 individuals who took colchicine 0.5 g once or twice daily for at least 1 month at any time during the vaccination period had a “markedly reduced” risk for flare relative to those who did not (adjusted OR=0.53), report Li et al in the Annals of the Rheumatic Diseases.

“This study may inform discussions with patients with gout about the risks of gout flare around the time of COVID-19 vaccination,” say the researchers.

They caution that their findings may not apply to other types of COVID-19 vaccine, which “need to be studied for validation, ideally prospectively and with multicentre collaboration.”

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group

4 May 2022: The coronavirus pandemic is affecting all healthcare professionals across the globe. Medicine Matters’ focus, in this difficult time, is the dissemination of the latest data to support you in your research and clinical practice, based on the scientific literature. We will update the information we provide on the site, as the data are published. However, please refer to your own professional and governmental guidelines for the latest guidance in your own country.

Ann Rheum Dis 2022; doi:10.1136/annrheumdis-2022-222199

share
SHARE
print
PRINT

New additions to the Adis Journal Club

A monthly selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

Rituximab and rheumatology practice in the COVID-19 era

How can rheumatologists respond to the challenges associated with rituximab use during the pandemic?